Abstract 530P
Background
Current comprehension of micropapillary lung adenocarcinoma (MP-LUAD) remains circumscribed to the realms of biological behaviors and genomic landscapes. Previous studies from our institute have shown that there exist subtle and unactionable genomic alterations between MP and non-MP early-stage lung adenocarcinoma (LUAD). Therefore, deciphering the unknown non-genomic regulatory network of MP-pattern malignancy may offer opportunities to uncover more tractable therapeutic targets for MP-LUAD patients.
Methods
A retrospective cohort of 66 surgical specimens from early-stage LUAD, including MP and other histologic subtypes, was mapped as discovery and validation cohorts. High-throughput screening was performed on cryosectioned and microscopically laser capture microdissected paired micropapillary and Acinar LUAD tissue. In vitro and in vivo experiments for validation were performed using co-culture of tumor associated macrophages (TAM) and tumor cells, xenograft mice and zebrafish models. ChIP-seq, CUT&Tag-seq and RNase I-PCR were employed to profile aberrant histone modifications, transcription factor occupying and chromatin accessibility in MP-LUAD.
Results
Bulk RNA-seq after microdissection showed aberrant activation of the MYC pathway in MP. MYC overexpression fostered MP-pattern malignancy of tumor tissue in immunocompetent mice, but not in vitro. Through screening via single-cell RNA-seq, retrospective cohort, and TCGA dataset, we found aberrant accumulation of TAMs around MP tissues. in vitro co-culture and in vivo dependency experiments demonstrated that MYC overexpression in tumor cells exhibited a MP-pattern malignancy in collaboration with TAMs. Follow-up experiments revealed that, MYC interacted with the pioneer transcription factor FOSL2 induced by TGFβ secreted from TAMs, aberrantly accessible chromatin, and induced epigenetic reprogramming of MP-pattern gene transcription.
Conclusions
Our study uncovered copy number amplification-induced activation of MYC in MP-LUAD, which by recruiting TAMs, cooperatively transcriptionally regulates MP pattern genes and promotes a metastatic malignancy.
Clinical trial identification
Editorial acknowledgement
We gratefully acknowledge all members of the Jiangsu Cancer Hospital Biobank and Department of Pathology for collection and storage of surgical samples used in this study. We gratefully acknowledge Ms. Luyuan Pan and Ms. Linglu Li from the China Zebrafish Resource Center for providing wild-type AB-line zebrafish and assistance with zebrafish-based experiments. We gratefully acknowledge instructions and guidance on DNase I-PCR experiments from Lu Wang Lab, Northwest University. We gratefully acknowledge plasmids from Wafik El-Deiry Lab and Andrea Califano Lab.
Legal entity responsible for the study
Nanjing Medical University Affiliated Cancer Hospital.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract